Jefferies Downgrades Marinus Pharma to Hold, Lowers Price Target to $0.5
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Andrew Tsai has downgraded Marinus Pharma from Buy to Hold and significantly lowered the price target from $5 to $0.5.
October 25, 2024 | 11:59 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Jefferies has downgraded Marinus Pharma from Buy to Hold, with a drastic reduction in the price target from $5 to $0.5, indicating a negative outlook.
The downgrade from Buy to Hold and the significant reduction in the price target from $5 to $0.5 by Jefferies suggests a negative outlook for Marinus Pharma. This is likely to lead to a decrease in investor confidence and a potential drop in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100